✦ LIBER ✦

Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist

✍ Scribed by Kana Taniguchi; Katsuhiro Shinjo; Mayumi Mizutani; Kaoru Shimada; Toshihisa Ishikawa; Frank S. Menniti; Atsushi Nagahisa

Book ID: 110003226
Publisher: Nature Publishing Group
Year: 1997
Tongue: English
Weight: 297 KB
Volume: 122
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bjp.0701445

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CP-101,606: An NR2B-Selective NMDA Recep

CP-101,606: An NR2B-Selective NMDA Receptor Antagonist

✍ Frank S. Menniti; Ajit K. Shah; Stephen A. Williams; Keith D. Wilner; W. Frost W 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

The effect of (±)-CP-101,606, an NMDA re

The effect of (±)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze

✍ Martin R. Guscott; Hannah F. Clarke; Fraser Murray; Sarah Grimwood; Linda J. Bri 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 322 KB

Antiparkinsonian Actions of CP-101,606,

Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d-Aspartate Receptors

✍ Kathy Steece-Collier; Leslie K. Chambers; Sarah S. Jaw-Tsai; Frank S. Menniti; J 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 66 KB

CP-101,606, an NR2B subunit selective NM

CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents

✍ Frank S Menniti; Martin J Pagnozzi; Paul Butler; Bertrand L Chenard; Sarah S Jaw 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 844 KB

Effects of a NR2B selective NMDA glutama

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism

✍ John G. Nutt; Steven A. Gunzler; Trish Kirchhoff; Penelope Hogarth; Jerry L. Wea 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

## Abstract Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double‐blind, placebo‐controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit sel

In vitro and antinociceptive profile of

In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist

✍ Sayoko Suetake-Koga; Toshiharu Shimazaki; Kazuaki Takamori; Shigeyuki Chaki; Kos 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 157 KB